Metraipolis › archive › dc_aa9ce2115ab3

Atypical hemolytic uremic syndrome — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-10T08:10:27.385Z
SHA-256 of the archived text
863d70f349006c17431d5b4273bb6fd371cb37d4f0680e8322ecc4dc56a75bc0
Stable URL of this page
https://metraipolis.com/documento/dc_aa9ce2115ab3

How to cite

Atypical hemolytic uremic syndrome — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_aa9ce2115ab3 (Metraipolis archive dc_aa9ce2115ab3, sha256 863d70f349006c17431d5b4273bb6fd371cb37d4f0680e8322ecc4dc56a75bc0)
BibTeX
@misc{dcaa9ce2115ab3,
  title = {Atypical hemolytic uremic syndrome — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_aa9ce2115ab3; sha256 863d70f349006c17431d5b4273bb6fd371cb37d4f0680e8322ecc4dc56a75bc0},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Atypical hemolytic uremic syndrome (aHUS), also known as complement-mediated hemolytic uremic syndrome (not to be confused with hemolytic–uremic syndrome), is an extremely rare, life-threatening, progressive disease that frequently has a genetic component. In most cases, it can be effectively controlled by interruption of the complement cascade. Particular monoclonal antibodies, discussed later in the article, have proven efficacy in many cases. aHUS is usually caused by chronic, uncontrolled activation of the complement system, a branch of the body's immune system that destroys and removes foreign particles. The disease affects both children and adults and is characterized by systemic thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, which can lead to stroke, heart attack, kidney failure, and death. The complement system activation may be due to mutations in the complement regulatory proteins (factor H, factor I, or membrane cofactor protein (CD46)), or occasionally due to acquired neutralizing autoantibody inhibitors of these complement system components (e.g. anti–factor H antibodies). Prior to availability of eculizumab (Soliris) and ravulizumab (Ultomiris), an estimated 33–40% of patients developed end-stage renal disease (ESRD) or died (despite the use of supportive care, e.g. plasmapheresis) with the first clinical bout of aHUS. Including subsequent relapses, a total of approximately two-thirds (65%) of patients required dialysis, had permanent renal damage, or died within the first year after diagnosis despite plasma exchange or plasma infusion (PE/PI).

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Atypical hemolytic uremic syndrome» — https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome
Wikidata Q17165460: «malattia» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q17165460
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1374236807, consultata il 2026-11-10T08:06:29.597Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 98182ba386c690ed7b644269441e152ca70ef4da68ab873c48bb4777145a0377